Sequential Single-Cell Transcriptional and Protein Marker Profiling Reveals TIGIT as a Marker of CD19 CAR-T Cell Dysfunction in Patients with Non-Hodgkin Lymphoma is a research paper published in Cancer Discovery (2022). On theSindex it has a DataRank of 0.673. It has been cited 88 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.673
From this paper's citation signal
Citation Network Contribution
0
Citation network not refreshed for this result
This paper's DataRank is currently driven only by its base citation score. Citation network data was not refreshed for this result.
Learn more about DataRank methodology →Case Comprehensive Cancer Center
Grant: P30CA043703
NIH
Grant: S10-NIH OD021559
NIH
Grant: T32AI089474
NIH HHS
Grant: S10 OD021559
National Institutes of Health
Grant: 1S10OD021559-01
Intermediate-Featured Flow Cytometer
National Institutes of Health
Grant: 3P30CA043703-20S1
Case Comprehensive Cancer Center Support Grant
National Institutes of Health
Grant: 2T32AI089474-06A1
Immunology Training Program-Predoctoral
FWCI
7.71
Citation Percentile
1.0%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma
Additional file 1 of TIGIT is the central player in T-cell suppression associated with CAR T-cell relapse in mantle cell lymphoma